{"id":326,"date":"2016-12-26T10:00:45","date_gmt":"2016-12-26T10:00:45","guid":{"rendered":"https:\/\/www.competitionlawyers.co.uk\/blog\/?p=326"},"modified":"2016-12-22T10:13:49","modified_gmt":"2016-12-22T10:13:49","slug":"pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing","status":"publish","type":"post","link":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing","title":{"rendered":"The pharmaceutical industry&#8217;s \u00a390 million fine for anti-competitive pricing"},"content":{"rendered":"<p>Earlier this month, the Competition and Markets Authority (CMA) issued an infringement decision that two companies had breached competition laws.<\/p>\n<p>The CMA found that Pfizer (Ltd and Inc) and Flynn Pharma (Ltd and Holdings) both abused their respective dominant positions by imposing unfair prices for phenytoin sodium capsules that they sold in the U.K. This infringed the Chapter II Prohibition of the Competition Act (CA) and Article 102 of the Treaty on the Functioning of the European Union (TFEU).<br \/>\n<!--more--><\/p>\n<p>Chapter II of the Competition Act details the abuse of a dominant position. In particular, section 18 details what kind of abuse constitutes to a breach, which can include, but isn&#8217;t limited to:<\/p>\n<div class=\"well\">\n<ul>\n<li>Imposing unfair purchase or selling prices or any other unfair trading conditions.<\/li>\n<li>Imposing unfair limitations, to the prejudice of consumers.<\/li>\n<li>Applying conditions that would put other trading parties at a disadvantage.<\/li>\n<li>Irrelevant supplementary obligations outside of the contractual terms.<\/li>\n<\/ul>\n<\/div>\n<p>Article 102 of the TFEU prohibits any abusive conduct by companies that have a dominant position on a particular market. The CMA is interested in investigating companies who are suspected to have breached this provision, as the main role of the provision is to regulate monopolies that may restrict competition and therefore produce worse outcomes for consumers and the market as a whole.<\/p>\n<p>Article 102&#8217;s provision reflects section 18 of the CA.<\/p>\n<h2>\u00a390 million penalty<\/h2>\n<p>As a result of their reported anti-competitive actions, the CMA has fined the pharmaceutical companies Pfizer and Flynn Pharma a combined total of \u00a389.4 million for charging over-excessive prices to the NHS for an anti-epilepsy drug.<\/p>\n<p>The fines were imposed after the companies increased their prices by up to 2,600 per cent overnight when the drug was de-branded in September 2012. The companies charged the NHS \u00a32.83 for a 100mg pack which shot up to \u00a367.50 before reducing it to \u00a354.00.<\/p>\n<p>As well as imposing a financial penalty, the CMA also has the power to impose enforcement actions on the companies. This was the case here as the CMA ordered the companies.<\/p>\n<h3>Anti-competitive behaviour<\/h3>\n<p>The Chairman of the Case Decision Group for the CMA&#8217;s investigation, Philip Marsden, noted that: <\/p>\n<blockquote><p>&#8220;&#8230;the companies deliberately exploited the opportunity offered by de-branding to hike up the price for a drug which is relied upon by many thousands of patients. These extraordinary price rises have cost the NHS and the taxpayer tens of millions of pounds.&#8221;<\/p><\/blockquote>\n<p>As Mr Marsden highlighted, the companies&#8217; anti-competitive conduct directly affected the consumers and the wider public i.e. the taxpayers.<\/p>\n<h3>Not looking bright for the pharmaceutical industry<\/h3>\n<p>The pharmaceutical industry is often looked at &#8211; right now, the CMA has four other ongoing investigations in to their activities.<\/p>\n<p>In February this year, the CMA imposed financial penalties totalling \u00a345 million for anti-competitive agreements in relation to the supply of the anti-depressant drug paroxetine.<\/p>\n<p><strong><u>Importance of competition laws<\/u><\/strong><\/p>\n<p>Without competition laws and policies, consumers and smaller businesses would suffer under the hands of dominant market players. Competition laws are there to ensure that companies can compete fairly, in turn this&#8217;ll create a wider choice for consumers, help reduce prices and improve quality in the marketplace.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Earlier this month, the Competition and Markets Authority (CMA) issued an infringement decision that two companies had breached competition laws. The CMA found that Pfizer (Ltd and Inc) and Flynn Pharma (Ltd and Holdings) both abused their respective dominant positions by imposing unfair prices for phenytoin sodium capsules that they sold in the U.K. This &hellip; <a href=\"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">The pharmaceutical industry&#8217;s \u00a390 million fine for anti-competitive pricing<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":90,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[8],"tags":[2],"class_list":["post-326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-price-hikes","tag-cma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmaceutical Industry&#039;s \u00a390 Million Fine For Anti-Competitive Pricing<\/title>\n<meta name=\"description\" content=\"The CMA found that Pfizer &amp; Flynn Pharma both abused their market positions by hiking prices up to 2,600% overnight costing the NHS and UK taxpayer millions\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical Industry&#039;s \u00a390 Million Fine For Anti-Competitive Pricing\" \/>\n<meta property=\"og:description\" content=\"The CMA found that Pfizer &amp; Flynn Pharma both abused their market positions by hiking prices up to 2,600% overnight costing the NHS and UK taxpayer millions\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\" \/>\n<meta property=\"og:site_name\" content=\"Competition Lawyers\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-26T10:00:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report_large-1024x682.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"682\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report_large.png?fit=1200%2C799&ssl=1\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/cee9a6aa77644666aa6ee448a4050035\"},\"headline\":\"The pharmaceutical industry&#8217;s \u00a390 million fine for anti-competitive pricing\",\"datePublished\":\"2016-12-26T10:00:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\"},\"wordCount\":522,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/pharmacy_merger_report.png?fit=725%2C250&ssl=1\",\"keywords\":[\"cma\"],\"articleSection\":[\"Price Hikes\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\",\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\",\"name\":\"Pharmaceutical Industry's \u00a390 Million Fine For Anti-Competitive Pricing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/pharmacy_merger_report.png?fit=725%2C250&ssl=1\",\"datePublished\":\"2016-12-26T10:00:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/cee9a6aa77644666aa6ee448a4050035\"},\"description\":\"The CMA found that Pfizer & Flynn Pharma both abused their market positions by hiking prices up to 2,600% overnight costing the NHS and UK taxpayer millions\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/pharmacy_merger_report.png?fit=725%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/pharmacy_merger_report.png?fit=725%2C250&ssl=1\",\"width\":725,\"height\":250,\"caption\":\"Pharmaceutical abuse\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The pharmaceutical industry&#8217;s \u00a390 million fine for anti-competitive pricing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/\",\"name\":\"Competition Lawyers\",\"description\":\"Latest Legal News, Cases &amp; Articles\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/cee9a6aa77644666aa6ee448a4050035\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4505b517753dbeadafd29fb3637a2013abb27430322735324a8f387db3295d37?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4505b517753dbeadafd29fb3637a2013abb27430322735324a8f387db3295d37?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4505b517753dbeadafd29fb3637a2013abb27430322735324a8f387db3295d37?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/author\\\/matthew\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmaceutical Industry's \u00a390 Million Fine For Anti-Competitive Pricing","description":"The CMA found that Pfizer & Flynn Pharma both abused their market positions by hiking prices up to 2,600% overnight costing the NHS and UK taxpayer millions","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing","og_locale":"en_GB","og_type":"article","og_title":"Pharmaceutical Industry's \u00a390 Million Fine For Anti-Competitive Pricing","og_description":"The CMA found that Pfizer & Flynn Pharma both abused their market positions by hiking prices up to 2,600% overnight costing the NHS and UK taxpayer millions","og_url":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing","og_site_name":"Competition Lawyers","article_published_time":"2016-12-26T10:00:45+00:00","og_image":[{"width":1024,"height":682,"url":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report_large-1024x682.png","type":"image\/png"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report_large.png?fit=1200%2C799&ssl=1","twitter_misc":{"Written by":"Admin","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#article","isPartOf":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing"},"author":{"name":"Admin","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/cee9a6aa77644666aa6ee448a4050035"},"headline":"The pharmaceutical industry&#8217;s \u00a390 million fine for anti-competitive pricing","datePublished":"2016-12-26T10:00:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing"},"wordCount":522,"commentCount":0,"image":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report.png?fit=725%2C250&ssl=1","keywords":["cma"],"articleSection":["Price Hikes"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing","url":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing","name":"Pharmaceutical Industry's \u00a390 Million Fine For Anti-Competitive Pricing","isPartOf":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage"},"image":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report.png?fit=725%2C250&ssl=1","datePublished":"2016-12-26T10:00:45+00:00","author":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/cee9a6aa77644666aa6ee448a4050035"},"description":"The CMA found that Pfizer & Flynn Pharma both abused their market positions by hiking prices up to 2,600% overnight costing the NHS and UK taxpayer millions","breadcrumb":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#primaryimage","url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report.png?fit=725%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report.png?fit=725%2C250&ssl=1","width":725,"height":250,"caption":"Pharmaceutical abuse"},{"@type":"BreadcrumbList","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/pharmaceutical-industry-90-million-fine-for-anti-competitive-pricing#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.competitionlawyers.co.uk\/blog"},{"@type":"ListItem","position":2,"name":"The pharmaceutical industry&#8217;s \u00a390 million fine for anti-competitive pricing"}]},{"@type":"WebSite","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#website","url":"https:\/\/www.competitionlawyers.co.uk\/blog\/","name":"Competition Lawyers","description":"Latest Legal News, Cases &amp; Articles","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.competitionlawyers.co.uk\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/cee9a6aa77644666aa6ee448a4050035","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/4505b517753dbeadafd29fb3637a2013abb27430322735324a8f387db3295d37?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4505b517753dbeadafd29fb3637a2013abb27430322735324a8f387db3295d37?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4505b517753dbeadafd29fb3637a2013abb27430322735324a8f387db3295d37?s=96&d=mm&r=g","caption":"Admin"},"url":"https:\/\/www.competitionlawyers.co.uk\/blog\/author\/matthew"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/08\/pharmacy_merger_report.png?fit=725%2C250&ssl=1","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=326"}],"version-history":[{"count":4,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/326\/revisions"}],"predecessor-version":[{"id":335,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/326\/revisions\/335"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media\/90"}],"wp:attachment":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}